bosentan anhydrous has been researched along with Orphan Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jachowicz, R; Krupa, A; Majda, D; Mozgawa, W; Szlęk, J | 1 |
| de Barros, CM; Papoila, AL | 1 |
2 other study(ies) available for bosentan anhydrous and Orphan Diseases
| Article | Year |
|---|---|
Physicochemical Properties of Bosentan and Selected PDE-5 Inhibitors in the Design of Drugs for Rare Diseases.
Topics: Bosentan; Drug Design; Humans; Hypertension, Pulmonary; Phosphodiesterase 5 Inhibitors; Rare Diseases; Sildenafil Citrate; Sulfonamides; Tadalafil | 2017 |
Therapeutic profile of orphan medicines.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Antineoplastic Agents; Bosentan; Caffeine; Central Nervous System Stimulants; Child; Child, Preschool; Citrates; Cross-Sectional Studies; Drug Labeling; Drug Prescriptions; Drug Utilization; Female; Humans; Immunologic Factors; Infant; Infant, Newborn; Male; Middle Aged; Orphan Drug Production; Pharmacy Service, Hospital; Portugal; Rare Diseases; Sulfonamides | 2007 |